Exelixis reported $355.98M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.47M 15.29M
Akebia Therapeutics AKBA:US $ 61.7M 2.09M
Amgen AMGN:US $ 6238M 608M
AstraZeneca AZN:LN 11390M 621M
Bayer BAYN:GR € 14639M 3521M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bluebird Bio BLUE:US $ 1.94M 0.34M
Bristol Myers Squibb BMY:US $ 11648M 337M
Cytokinetics CYTK:US $ 1.15M 54.45M
Eisai 4523:JP Y 190901M 12071M
Esperion Therapeutics ESPR:US $ 18.84M 3.44M
Exelixis EXEL:US $ 355.98M 95.16M
Genmab GEN:DC DK 2119M 500M
Glaxosmithkline GSK:US $ 9780M 253M
Immunogen IMGN:US $ 38.08M 10.09M
Merk MRK:US $ 15901M 2380M
Mirati Therapeutics MRTX:US $ 0.71M 0.41M
Nektar Therapeutics NKTR:US $ 25.01M 0.09M
Novartis NOVN:VX SF 12814M 708M
Takeda 4502:JP Y 873289M 28005M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
Xencor XNCR:US $ 85.5M 68.52M